Indivior Pharmaceuticals (INDV) Company Report

Analyst Earnings Quarterly Reports

Earnings summaries and quarterly performance for Indivior Pharmaceuticals.

Analyst Coverage

Research analysts who have asked questions during Indivior Pharmaceuticals earnings calls.

Chase Knickerbocker

Craig-Hallum Capital Group

6 questions for INDV

Also covers: AVDL, BFLY, BVS +17 more

David Amsellem

Piper Sandler Companies

6 questions for INDV

Also covers: ABBV, ALKS, AMGN +27 more

Christian Glennie

Stifel

5 questions for INDV

Thibault Boutherin

Morgan Stanley

4 questions for INDV

Also covers: ALVO, EVO, GRFS +2 more

Brandon Folkes

Rodman & Renshaw

3 questions for INDV

Also covers: ACHV, ANIP, AVDL +12 more

Dennis Ding

Jefferies Financial Group Inc.

3 questions for INDV

Also covers: ARDX, CARA, CRNX +9 more

Paul Cuddon

Deutsche Numis

3 questions for INDV

Also covers: MXCT

Brian Balchin

Jefferies

1 question for INDV

Carl Byrnes

Northland Capital Markets

1 question for INDV

Also covers: ALVO, BLFS, BWAY +6 more

Latest news

Recent press releases and 8-K filings for INDV.

Indivior Reports Q4 and FY 2025 Results, Provides 2026 Guidance, and Authorizes Share Repurchase Program

INDV

Earnings

Guidance Update

Share Buyback

Indivior reported FY 2025 Total Net Revenue of $1,239 million and SUBLOCADE Net Revenue of $856 million, marking a 13% increase for SUBLOCADE year-over-year.
Adjusted EBITDA for FY 2025 was $428 million, a 20% increase from FY 2024, with the Adjusted EBITDA margin expanding by 5 percentage points to 35%.
For 2026, the company provides guidance for Total Net Revenue between $1,125 million and $1,195 million, SUBLOCADE Net Revenue between $905 million and $945 million, and Adjusted EBITDA between $535 million and $575 million.
Indivior entered Phase II of its Indivior Action Agenda in January 2026, aiming to accelerate U.S. SUBLOCADE dispense unit growth to mid-teens in 2026 from 7% in 2025.
The company authorized a ~$400 million share repurchase program in February 2026, with a term of up to 18 months.

2 days ago

Presentation

Indivior Reports Strong 2025 Results, Issues Optimistic 2026 Guidance, and Authorizes Share Repurchase Program

INDV

Earnings

Guidance Update

Share Buyback

Indivior reported strong financial results for full-year 2025, with total net revenue of $1.24 billion (up 4% year-over-year) and SUBLOCADE net revenue of $856 million (up 13% year-over-year). Adjusted EBITDA grew 20% to $428 million.
The company provided optimistic 2026 guidance, projecting SUBLOCADE net revenue between $905 million and $945 million (8% growth at midpoint) and adjusted EBITDA between $535 million and $575 million (30% growth at midpoint), with a 13 percentage point margin expansion to 48%.
Indivior's board authorized a new $400 million share repurchase program, and the company expects to generate approximately $300 million in cash flow from operations in 2026, following the payment of a $295 million legacy DOJ obligation in 2025.
The company is progressing with its "Indivior Action Agenda," having completed Phase 1 and now executing Phase 2 "Accelerate," focusing on SUBLOCADE growth and evaluating business development opportunities in new therapeutic areas.

2 days ago

Transcript

Indivior Reports Q4 and Full Year 2025 Results, Provides 2026 Guidance, and Authorizes Share Repurchase Program

INDV

Earnings

Guidance Update

Share Buyback

For the full year 2025, Indivior reported total net revenue of $1.24 billion, a 4% increase compared to the prior year, with SUBLOCADE net revenue growing 13% to $856 million. Adjusted EBITDA increased 20% year-over-year to $428 million.
Indivior provided 2026 guidance, expecting SUBLOCADE net revenue between $905 million and $945 million (8% growth at the midpoint) and adjusted EBITDA between $535 million and $575 million (30% growth at the midpoint compared to 2025).
The company anticipates SUBLOCADE dispense unit growth to accelerate to mid-teens in 2026, up from 7% in 2025.
Indivior's board authorized a new $400 million share repurchase program with a term of up to 18 months, which the company plans to utilize opportunistically.
The company is also evaluating business development opportunities for commercial stage assets in new therapeutic areas, seeking products with peak sales potential greater than $200 million and a long runway.

2 days ago

Transcript

Indivior Pharmaceuticals Reports Q4 and Full Year 2025 Results and Provides 2026 Guidance

INDV

Earnings

Guidance Update

Share Buyback

Indivior Pharmaceuticals reported total net revenue of $1.24 billion for the full year 2025, a 4% increase compared to the prior year, with SUBLOCADE net revenue reaching a record $856 million, up 13% versus 2024. Adjusted EBITDA grew 20% year-over-year to $428 million in 2025, with a 500 basis point margin improvement.
The company successfully completed Phase I of its Indivior Action Agenda, "Generate Momentum," and is now executing Phase II, "Accelerate," which aims to accelerate SUBLOCADE dispense unit growth and net revenue throughout 2026. SUBLOCADE dispense volume grew 7% in 2025, with Q4 dispense unit growth of 12% year-over-year.
For 2026, Indivior expects total net revenue in the range of $1.125 billion-$1.195 billion, with SUBLOCADE net revenue projected between $905 million-$945 million, representing 8% growth at the midpoint versus 2025. They anticipate adjusted EBITDA in the range of $535 million-$575 million, a 30% increase at the midpoint compared to 2025, and expect to generate over $300 million in cash flow from operations.
Indivior's board authorized a new $400 million share repurchase program with a term of up to 18 months, which will be utilized opportunistically as part of their capital deployment strategy, alongside managing debt and evaluating business development opportunities.

2 days ago

Transcript

Indivior Reports Q4 and Full-Year 2025 Financial Results, Issues 2026 Guidance, and Authorizes Share Repurchase

INDV

Earnings

Guidance Update

Share Buyback

Indivior reported record total SUBLOCADE net revenue of $252 million for Q4 2025 and $856 million for full-year 2025. The company also achieved GAAP net income of $102 million (Q4 2025) and $210 million (FY 2025), and Adjusted EBITDA of $142 million (Q4 2025) and $428 million (FY 2025).
The company reaffirmed its full-year 2026 financial guidance, projecting Total Net Revenue between $1,125 million and $1,195 million, Total SUBLOCADE Net Revenue between $905 million and $945 million, and Adjusted EBITDA between $535 million and $575 million. Additionally, approximately $300 million in cash flow from operations is expected in 2026.
Indivior authorized a new $400 million share repurchase program in February 2026.
The company concluded its legacy U.S. Department of Justice matter on November 20, 2025, by paying the outstanding obligation of $295 million.
Indivior completed its redomiciliation from the United Kingdom to the United States on January 26, 2026, and entered Phase II of the Indivior Action Agenda – Accelerate – on January 1, 2026.

2 days ago

8-K

Indivior Reports FY 2025 Results and Provides 2026 Financial Guidance

INDV

Earnings

Guidance Update

Share Buyback

Indivior reported total net revenue of $1,239 million and Adjusted EBITDA of $428 million for fiscal year 2025, with SUBLOCADE net revenue reaching $856 million.
For 2026, the company expects total net revenue between $1,125 million and $1,195 million, with SUBLOCADE net revenue projected to be $905 million to $945 million. Adjusted EBITDA is guided to be $535 million to $575 million, and non-GAAP operating expenses are not expected to exceed $450 million.
The company anticipates approximately $300 million in cash flow from operations in 2026 and authorized a ~$400 million share repurchase program in February 2026.
Indivior completed Phase I of its Action Agenda in 2025 and entered Phase II in January 2026, focusing on accelerating U.S. SUBLOCADE dispense unit growth to mid-teens and immediately accelerating Adjusted EBITDA and cash flow at a faster rate.

2 days ago

Presentation

Indivior Completes Redomiciliation to the United States

INDV

Corporate Governance

Delisting/Listing Issues

Indivior completed its redomiciliation from the United Kingdom to the United States, with Indivior Pharmaceuticals, Inc., a Delaware corporation, becoming the new parent company.
Indivior PLC was renamed Indivior Ltd. and is now a wholly-owned subsidiary of Indivior Pharmaceuticals, Inc..
The common stock of Indivior Pharmaceuticals, Inc. began trading on Nasdaq under the symbol "INDV" on January 26, 2026, replacing Indivior PLC ordinary shares which ceased trading on January 23, 2026.
Shareholders of Indivior PLC received one new Indivior Pharmaceuticals, Inc. common share for each Indivior PLC ordinary share held.

Jan 26, 2026, 12:01 PM

8-K

Indivior Completes Redomiciliation to the United States

INDV

Delisting/Listing Issues

Proxy Vote Outcomes

Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) completed its redomiciliation from the United Kingdom to the United States on January 26, 2026.
A new Delaware corporation, Indivior Pharmaceuticals, Inc. ("IPI"), has become the new parent company, with Indivior PLC renamed Indivior Ltd. and becoming a wholly-owned subsidiary of IPI.
The common stock of IPI will continue to trade on Nasdaq under the symbol "INDV".
Shareholders of Indivior PLC received one new IPI common share for each Indivior PLC ordinary share held.
Indivior expects benefits from the redomiciliation to include strengthening its U.S. capital markets presence, increasing potential U.S. equity indexation, and simplifying corporate governance.

Jan 26, 2026, 12:00 PM

Press Release

Indivior PLC Provides Full-Year 2026 Financial Guidance and Business Update

INDV

Guidance Update

Revenue Acceleration/Inflection

Indivior PLC issued full-year 2026 financial guidance, projecting Total Net Revenue between $1,125 million and $1,195 million and Adjusted EBITDA between $535 million and $575 million.
The company expects Total SUBLOCADE Net Revenue to reach $905 million to $945 million, reflecting 11% growth at the midpoint, driven by an acceleration of U.S. SUBLOCADE dispense unit growth to the mid-teens.
Non-GAAP Operating Expenses are forecast to be $430 million to $450 million, benefiting from at least $150 million in annual savings due to a simplified operating model.
Indivior anticipates 35% Adjusted EBITDA growth and a 14 percentage point expansion in Adjusted EBITDA margin to 48% in 2026, as it enters Phase II of its Action Agenda focused on acceleration.

Jan 8, 2026, 12:05 PM

8-K

Indivior Announces Positive Clinical Trial Results for SUBLOCADE

INDV

Product Launch

Indivior PLC announced that a clinical trial published in JAMA Network Open showed its SUBLOCADE® (extended-release buprenorphine) rapidly reduced opioid use and improved opioid abstinence in individuals with moderate-to-severe opioid use disorder (OUD).
Both the 100-mg and 300-mg monthly maintenance doses were well-tolerated with no new safety signals identified.
Post-hoc analyses indicated that the 300-mg monthly maintenance dose performed significantly better than the 100-mg monthly dose in participants reporting high-frequency fentanyl use.

Dec 17, 2025, 4:30 PM

Press Release